INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31301, 29073, 'Vinblastine', 'Liver Diseases', 'Vinblastine is metabolized by the liver and eliminated primarily via biliary excretion.  Patients with hepatic impairment may be at increased risk for toxicity associated with vinblastine therapy.  Therapy with vinblastine should be administered cautiously in patients with compromised hepatic function.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31302, 10135, 'Vigabatrin', 'Blindness', 'Vigabatrin causes permanent bilateral concentric visual field constriction.  The onset of vision loss from vigabatrin is unpredictable, and can occur within weeks of starting treatment or sooner, or at any time after starting treatment, even after months or years.  The risk of vision loss increases with increasing dose and cumulative exposure, but there is no dose or exposure known to be free of risk of vision loss.  Because of the risk of vision loss, and because, when it is effective, vigabatrin provides an observable symptomatic benefit, patient response and continued need for treatment should be periodically assessed.  If the need clearly outweighs the risk, caution should be exercised when using vigabatrin therapy in patients with, or at high risk of, other types of irreversible vision loss.  Vigabatrin should not be used in patients that are being treated for retinopathy or glaucoma.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31303, 10135, 'Vigabatrin', 'Depressive Disorder', 'Antiepileptic drugs (AEDs) have been associated with an increased risk of suicidal thoughts or behavior in patients taking these drugs for any indication.  Pooled analyses of 199 placebo-controlled clinical studies involving the use of 11 different AEDs showed that patients receiving AEDs had approximately twice the risk of suicidal thinking or behavior compared to patients receiving placebo.  AEDs should be administered cautiously in patients with depression or other psychiatric disorders.  The risk of suicidal thoughts and behavior should be carefully assessed against the risk of untreated illness, bearing in mind that epilepsy and many other conditions for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior.  Patients, caregivers, and families should be alert to the emergence or worsening of signs and symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts or behavior.  If patients have symptoms of suicidal ideation or behavior, a dosage reduction or treatment discontinuation should be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31304, 10135, 'Vigabatrin', 'Neurotoxicity Syndromes', 'Vigabatrin has produced pathological changes in the brains of rats and long-term neurobehavioral abnormalities (convulsions, neuromotor impairment, learning deficits) were also observed.  In humans, abnormal MRI signal changes characterized by increased T2 signal and restricted diffusion in a symmetric pattern involving the thalamus, basal ganglia, brain stem, and cerebellum have been observed in some infants treated for infantile spasms (IS) with vigabatrin.  Studies of the effects of vigabatrin on MRI and changes in visual and somatosensory evoked potentials (EP) in adult epilepsy patients have not been clearly defined.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31305, 10135, 'Vigabatrin', 'Peripheral Nervous System Diseases', 'Vigabatrin causes symptoms of peripheral neuropathy in adults.  There is insufficient evidence to determine if development of these signs and symptoms were related to duration of vigabatrin treatment, cumulative dose, or if the findings of peripheral neuropathy were completely reversible upon discontinuation of vigabatrin.  Therapy with vigabatrin should be administered cautiously in patients with peripheral neuropathy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31306, 29310, 'Vilazodone', 'Depressive Disorder', 'Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials; these trials did not show increased risk in patients older than 24 years and risk was reduced in patients 65 years and older.  Adult and pediatric patients with major depressive disorder may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressants; this risk may persist until significant remission occurs.  Suicide is a known risk of depression and certain other psychiatric disorders; such disorders are the strongest predictors of suicide.  Patients of all ages treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the first few months of drug therapy, and at times of dose changes.  Family members/caregivers should be advised to monitor for changes in behavior and to notify the health care provider.  Changing the therapeutic regimen (including discontinuing the medication) should be considered in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31307, 29311, 'Vilazodone', 'Depressive Disorder', 'Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials; these trials did not show increased risk in patients older than 24 years and risk was reduced in patients 65 years and older.  Adult and pediatric patients with major depressive disorder may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressants; this risk may persist until significant remission occurs.  Suicide is a known risk of depression and certain other psychiatric disorders; such disorders are the strongest predictors of suicide.  Patients of all ages treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the first few months of drug therapy, and at times of dose changes.  Family members/caregivers should be advised to monitor for changes in behavior and to notify the health care provider.  Changing the therapeutic regimen (including discontinuing the medication) should be considered in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31308, 29312, 'Vilazodone', 'Depressive Disorder', 'Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials; these trials did not show increased risk in patients older than 24 years and risk was reduced in patients 65 years and older.  Adult and pediatric patients with major depressive disorder may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressants; this risk may persist until significant remission occurs.  Suicide is a known risk of depression and certain other psychiatric disorders; such disorders are the strongest predictors of suicide.  Patients of all ages treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the first few months of drug therapy, and at times of dose changes.  Family members/caregivers should be advised to monitor for changes in behavior and to notify the health care provider.  Changing the therapeutic regimen (including discontinuing the medication) should be considered in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31309, 29314, 'Vilazodone', 'Depressive Disorder', 'Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials; these trials did not show increased risk in patients older than 24 years and risk was reduced in patients 65 years and older.  Adult and pediatric patients with major depressive disorder may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressants; this risk may persist until significant remission occurs.  Suicide is a known risk of depression and certain other psychiatric disorders; such disorders are the strongest predictors of suicide.  Patients of all ages treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the first few months of drug therapy, and at times of dose changes.  Family members/caregivers should be advised to monitor for changes in behavior and to notify the health care provider.  Changing the therapeutic regimen (including discontinuing the medication) should be considered in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31310, 29315, 'Vilazodone', 'Depressive Disorder', 'Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials; these trials did not show increased risk in patients older than 24 years and risk was reduced in patients 65 years and older.  Adult and pediatric patients with major depressive disorder may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressants; this risk may persist until significant remission occurs.  Suicide is a known risk of depression and certain other psychiatric disorders; such disorders are the strongest predictors of suicide.  Patients of all ages treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the first few months of drug therapy, and at times of dose changes.  Family members/caregivers should be advised to monitor for changes in behavior and to notify the health care provider.  Changing the therapeutic regimen (including discontinuing the medication) should be considered in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31311, 29316, 'Vilazodone', 'Depressive Disorder', 'Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials; these trials did not show increased risk in patients older than 24 years and risk was reduced in patients 65 years and older.  Adult and pediatric patients with major depressive disorder may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressants; this risk may persist until significant remission occurs.  Suicide is a known risk of depression and certain other psychiatric disorders; such disorders are the strongest predictors of suicide.  Patients of all ages treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the first few months of drug therapy, and at times of dose changes.  Family members/caregivers should be advised to monitor for changes in behavior and to notify the health care provider.  Changing the therapeutic regimen (including discontinuing the medication) should be considered in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31312, 29317, 'Vilazodone', 'Depressive Disorder', 'Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials; these trials did not show increased risk in patients older than 24 years and risk was reduced in patients 65 years and older.  Adult and pediatric patients with major depressive disorder may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressants; this risk may persist until significant remission occurs.  Suicide is a known risk of depression and certain other psychiatric disorders; such disorders are the strongest predictors of suicide.  Patients of all ages treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the first few months of drug therapy, and at times of dose changes.  Family members/caregivers should be advised to monitor for changes in behavior and to notify the health care provider.  Changing the therapeutic regimen (including discontinuing the medication) should be considered in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31313, 29310, 'Vilazodone', 'Glaucoma, Angle-Closure', 'Some antidepressants exert mydriatic activity that can induce increased intraocular pressure and result in angle-closure (narrow-angle) glaucoma in a patient with anatomically narrow angles who does not have a patent iridectomy.  Prior to initiating therapy with these agents, patients should be examined to determine whether they are susceptible to angle closure, and have a prophylactic procedure (e.g., iridectomy), if they are susceptible.  The use of these drugs in patients with untreated anatomically narrow angles should be avoided.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31314, 29311, 'Vilazodone', 'Glaucoma, Angle-Closure', 'Some antidepressants exert mydriatic activity that can induce increased intraocular pressure and result in angle-closure (narrow-angle) glaucoma in a patient with anatomically narrow angles who does not have a patent iridectomy.  Prior to initiating therapy with these agents, patients should be examined to determine whether they are susceptible to angle closure, and have a prophylactic procedure (e.g., iridectomy), if they are susceptible.  The use of these drugs in patients with untreated anatomically narrow angles should be avoided.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31315, 29312, 'Vilazodone', 'Glaucoma, Angle-Closure', 'Some antidepressants exert mydriatic activity that can induce increased intraocular pressure and result in angle-closure (narrow-angle) glaucoma in a patient with anatomically narrow angles who does not have a patent iridectomy.  Prior to initiating therapy with these agents, patients should be examined to determine whether they are susceptible to angle closure, and have a prophylactic procedure (e.g., iridectomy), if they are susceptible.  The use of these drugs in patients with untreated anatomically narrow angles should be avoided.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31316, 29314, 'Vilazodone', 'Glaucoma, Angle-Closure', 'Some antidepressants exert mydriatic activity that can induce increased intraocular pressure and result in angle-closure (narrow-angle) glaucoma in a patient with anatomically narrow angles who does not have a patent iridectomy.  Prior to initiating therapy with these agents, patients should be examined to determine whether they are susceptible to angle closure, and have a prophylactic procedure (e.g., iridectomy), if they are susceptible.  The use of these drugs in patients with untreated anatomically narrow angles should be avoided.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31317, 29315, 'Vilazodone', 'Glaucoma, Angle-Closure', 'Some antidepressants exert mydriatic activity that can induce increased intraocular pressure and result in angle-closure (narrow-angle) glaucoma in a patient with anatomically narrow angles who does not have a patent iridectomy.  Prior to initiating therapy with these agents, patients should be examined to determine whether they are susceptible to angle closure, and have a prophylactic procedure (e.g., iridectomy), if they are susceptible.  The use of these drugs in patients with untreated anatomically narrow angles should be avoided.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31318, 29316, 'Vilazodone', 'Glaucoma, Angle-Closure', 'Some antidepressants exert mydriatic activity that can induce increased intraocular pressure and result in angle-closure (narrow-angle) glaucoma in a patient with anatomically narrow angles who does not have a patent iridectomy.  Prior to initiating therapy with these agents, patients should be examined to determine whether they are susceptible to angle closure, and have a prophylactic procedure (e.g., iridectomy), if they are susceptible.  The use of these drugs in patients with untreated anatomically narrow angles should be avoided.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31319, 29317, 'Vilazodone', 'Glaucoma, Angle-Closure', 'Some antidepressants exert mydriatic activity that can induce increased intraocular pressure and result in angle-closure (narrow-angle) glaucoma in a patient with anatomically narrow angles who does not have a patent iridectomy.  Prior to initiating therapy with these agents, patients should be examined to determine whether they are susceptible to angle closure, and have a prophylactic procedure (e.g., iridectomy), if they are susceptible.  The use of these drugs in patients with untreated anatomically narrow angles should be avoided.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31320, 29310, 'Vilazodone', 'Hemorrhage', 'Some antidepressants should be administered with caution in patients with an increased risk for hemorrhage.  Patients should be advised to immediately report any signs and symptoms suggestive of bleeding complications, including ecchymosis, hematoma, epistaxis, and petechia.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31321, 29311, 'Vilazodone', 'Hemorrhage', 'Some antidepressants should be administered with caution in patients with an increased risk for hemorrhage.  Patients should be advised to immediately report any signs and symptoms suggestive of bleeding complications, including ecchymosis, hematoma, epistaxis, and petechia.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31322, 29312, 'Vilazodone', 'Hemorrhage', 'Some antidepressants should be administered with caution in patients with an increased risk for hemorrhage.  Patients should be advised to immediately report any signs and symptoms suggestive of bleeding complications, including ecchymosis, hematoma, epistaxis, and petechia.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31323, 29314, 'Vilazodone', 'Hemorrhage', 'Some antidepressants should be administered with caution in patients with an increased risk for hemorrhage.  Patients should be advised to immediately report any signs and symptoms suggestive of bleeding complications, including ecchymosis, hematoma, epistaxis, and petechia.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31324, 29315, 'Vilazodone', 'Hemorrhage', 'Some antidepressants should be administered with caution in patients with an increased risk for hemorrhage.  Patients should be advised to immediately report any signs and symptoms suggestive of bleeding complications, including ecchymosis, hematoma, epistaxis, and petechia.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31325, 29316, 'Vilazodone', 'Hemorrhage', 'Some antidepressants should be administered with caution in patients with an increased risk for hemorrhage.  Patients should be advised to immediately report any signs and symptoms suggestive of bleeding complications, including ecchymosis, hematoma, epistaxis, and petechia.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31326, 29317, 'Vilazodone', 'Hemorrhage', 'Some antidepressants should be administered with caution in patients with an increased risk for hemorrhage.  Patients should be advised to immediately report any signs and symptoms suggestive of bleeding complications, including ecchymosis, hematoma, epistaxis, and petechia.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31327, 29310, 'Vilazodone', 'Hyponatremia', 'Treatment with vilazodone may cause hyponatremia, in many cases secondary to development of the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).  Caution should be used when treating patients with hyponatremia or at greater risk of developing hyponatremia such as elderly patients, patients taking diuretics or those who are volume-depleted.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31328, 29311, 'Vilazodone', 'Hyponatremia', 'Treatment with vilazodone may cause hyponatremia, in many cases secondary to development of the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).  Caution should be used when treating patients with hyponatremia or at greater risk of developing hyponatremia such as elderly patients, patients taking diuretics or those who are volume-depleted.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31329, 29312, 'Vilazodone', 'Hyponatremia', 'Treatment with vilazodone may cause hyponatremia, in many cases secondary to development of the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).  Caution should be used when treating patients with hyponatremia or at greater risk of developing hyponatremia such as elderly patients, patients taking diuretics or those who are volume-depleted.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31330, 29314, 'Vilazodone', 'Hyponatremia', 'Treatment with vilazodone may cause hyponatremia, in many cases secondary to development of the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).  Caution should be used when treating patients with hyponatremia or at greater risk of developing hyponatremia such as elderly patients, patients taking diuretics or those who are volume-depleted.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31331, 29315, 'Vilazodone', 'Hyponatremia', 'Treatment with vilazodone may cause hyponatremia, in many cases secondary to development of the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).  Caution should be used when treating patients with hyponatremia or at greater risk of developing hyponatremia such as elderly patients, patients taking diuretics or those who are volume-depleted.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31332, 29316, 'Vilazodone', 'Hyponatremia', 'Treatment with vilazodone may cause hyponatremia, in many cases secondary to development of the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).  Caution should be used when treating patients with hyponatremia or at greater risk of developing hyponatremia such as elderly patients, patients taking diuretics or those who are volume-depleted.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31333, 29317, 'Vilazodone', 'Hyponatremia', 'Treatment with vilazodone may cause hyponatremia, in many cases secondary to development of the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).  Caution should be used when treating patients with hyponatremia or at greater risk of developing hyponatremia such as elderly patients, patients taking diuretics or those who are volume-depleted.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31334, 29310, 'Vilazodone', 'Bipolar Disorder', 'Therapy with vilazodone may cause activation of mania and hypomania and should be used with caution in patients with personal or family history of mania, hypomania, bipolar disorder, and other mood disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31335, 29311, 'Vilazodone', 'Bipolar Disorder', 'Therapy with vilazodone may cause activation of mania and hypomania and should be used with caution in patients with personal or family history of mania, hypomania, bipolar disorder, and other mood disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31336, 29312, 'Vilazodone', 'Bipolar Disorder', 'Therapy with vilazodone may cause activation of mania and hypomania and should be used with caution in patients with personal or family history of mania, hypomania, bipolar disorder, and other mood disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31337, 29314, 'Vilazodone', 'Bipolar Disorder', 'Therapy with vilazodone may cause activation of mania and hypomania and should be used with caution in patients with personal or family history of mania, hypomania, bipolar disorder, and other mood disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31338, 29315, 'Vilazodone', 'Bipolar Disorder', 'Therapy with vilazodone may cause activation of mania and hypomania and should be used with caution in patients with personal or family history of mania, hypomania, bipolar disorder, and other mood disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31339, 29316, 'Vilazodone', 'Bipolar Disorder', 'Therapy with vilazodone may cause activation of mania and hypomania and should be used with caution in patients with personal or family history of mania, hypomania, bipolar disorder, and other mood disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31340, 29317, 'Vilazodone', 'Bipolar Disorder', 'Therapy with vilazodone may cause activation of mania and hypomania and should be used with caution in patients with personal or family history of mania, hypomania, bipolar disorder, and other mood disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31341, 29310, 'Vilazodone', 'Epilepsy', 'Therapy with vilazodone should be administered cautiously in patients with epilepsy or a history of seizure disorder.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31342, 29311, 'Vilazodone', 'Epilepsy', 'Therapy with vilazodone should be administered cautiously in patients with epilepsy or a history of seizure disorder.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31343, 29312, 'Vilazodone', 'Epilepsy', 'Therapy with vilazodone should be administered cautiously in patients with epilepsy or a history of seizure disorder.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31344, 29314, 'Vilazodone', 'Epilepsy', 'Therapy with vilazodone should be administered cautiously in patients with epilepsy or a history of seizure disorder.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31345, 29315, 'Vilazodone', 'Epilepsy', 'Therapy with vilazodone should be administered cautiously in patients with epilepsy or a history of seizure disorder.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31346, 29316, 'Vilazodone', 'Epilepsy', 'Therapy with vilazodone should be administered cautiously in patients with epilepsy or a history of seizure disorder.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31347, 29317, 'Vilazodone', 'Epilepsy', 'Therapy with vilazodone should be administered cautiously in patients with epilepsy or a history of seizure disorder.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31348, 23315, 'Vinorelbine', 'Respiratory Insufficiency', 'Acute shortness of breath and bronchospasm, some severe and life-threatening, have been reported with the use of vinca alkaloids.  These reactions were observed most often during combination therapy with mitomycin C, occurring within minutes to several hours after administration of the vinca alkaloid or up to 2 weeks following the mitomycin dose.  Therapy with vinca alkaloids should be administered cautiously in patients with preexisting pulmonary dysfunction.  Aggressive treatment may be necessary, including use of supplemental oxygen, bronchodilators, and/or corticosteroids.  In patients who develop progressive dyspnea requiring chronic therapy, vinca alkaloid should not be readministered.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31349, 23316, 'Vinorelbine', 'Respiratory Insufficiency', 'Acute shortness of breath and bronchospasm, some severe and life-threatening, have been reported with the use of vinca alkaloids.  These reactions were observed most often during combination therapy with mitomycin C, occurring within minutes to several hours after administration of the vinca alkaloid or up to 2 weeks following the mitomycin dose.  Therapy with vinca alkaloids should be administered cautiously in patients with preexisting pulmonary dysfunction.  Aggressive treatment may be necessary, including use of supplemental oxygen, bronchodilators, and/or corticosteroids.  In patients who develop progressive dyspnea requiring chronic therapy, vinca alkaloid should not be readministered.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31350, 23317, 'Vinorelbine', 'Respiratory Insufficiency', 'Acute shortness of breath and bronchospasm, some severe and life-threatening, have been reported with the use of vinca alkaloids.  These reactions were observed most often during combination therapy with mitomycin C, occurring within minutes to several hours after administration of the vinca alkaloid or up to 2 weeks following the mitomycin dose.  Therapy with vinca alkaloids should be administered cautiously in patients with preexisting pulmonary dysfunction.  Aggressive treatment may be necessary, including use of supplemental oxygen, bronchodilators, and/or corticosteroids.  In patients who develop progressive dyspnea requiring chronic therapy, vinca alkaloid should not be readministered.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31351, 23318, 'Vinorelbine', 'Respiratory Insufficiency', 'Acute shortness of breath and bronchospasm, some severe and life-threatening, have been reported with the use of vinca alkaloids.  These reactions were observed most often during combination therapy with mitomycin C, occurring within minutes to several hours after administration of the vinca alkaloid or up to 2 weeks following the mitomycin dose.  Therapy with vinca alkaloids should be administered cautiously in patients with preexisting pulmonary dysfunction.  Aggressive treatment may be necessary, including use of supplemental oxygen, bronchodilators, and/or corticosteroids.  In patients who develop progressive dyspnea requiring chronic therapy, vinca alkaloid should not be readministered.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31352, 29366, 'Vinorelbine', 'Respiratory Insufficiency', 'Acute shortness of breath and bronchospasm, some severe and life-threatening, have been reported with the use of vinca alkaloids.  These reactions were observed most often during combination therapy with mitomycin C, occurring within minutes to several hours after administration of the vinca alkaloid or up to 2 weeks following the mitomycin dose.  Therapy with vinca alkaloids should be administered cautiously in patients with preexisting pulmonary dysfunction.  Aggressive treatment may be necessary, including use of supplemental oxygen, bronchodilators, and/or corticosteroids.  In patients who develop progressive dyspnea requiring chronic therapy, vinca alkaloid should not be readministered.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31353, 29367, 'Vinorelbine', 'Respiratory Insufficiency', 'Acute shortness of breath and bronchospasm, some severe and life-threatening, have been reported with the use of vinca alkaloids.  These reactions were observed most often during combination therapy with mitomycin C, occurring within minutes to several hours after administration of the vinca alkaloid or up to 2 weeks following the mitomycin dose.  Therapy with vinca alkaloids should be administered cautiously in patients with preexisting pulmonary dysfunction.  Aggressive treatment may be necessary, including use of supplemental oxygen, bronchodilators, and/or corticosteroids.  In patients who develop progressive dyspnea requiring chronic therapy, vinca alkaloid should not be readministered.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31354, 29368, 'Vinorelbine', 'Respiratory Insufficiency', 'Acute shortness of breath and bronchospasm, some severe and life-threatening, have been reported with the use of vinca alkaloids.  These reactions were observed most often during combination therapy with mitomycin C, occurring within minutes to several hours after administration of the vinca alkaloid or up to 2 weeks following the mitomycin dose.  Therapy with vinca alkaloids should be administered cautiously in patients with preexisting pulmonary dysfunction.  Aggressive treatment may be necessary, including use of supplemental oxygen, bronchodilators, and/or corticosteroids.  In patients who develop progressive dyspnea requiring chronic therapy, vinca alkaloid should not be readministered.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31355, 29369, 'Vinorelbine', 'Respiratory Insufficiency', 'Acute shortness of breath and bronchospasm, some severe and life-threatening, have been reported with the use of vinca alkaloids.  These reactions were observed most often during combination therapy with mitomycin C, occurring within minutes to several hours after administration of the vinca alkaloid or up to 2 weeks following the mitomycin dose.  Therapy with vinca alkaloids should be administered cautiously in patients with preexisting pulmonary dysfunction.  Aggressive treatment may be necessary, including use of supplemental oxygen, bronchodilators, and/or corticosteroids.  In patients who develop progressive dyspnea requiring chronic therapy, vinca alkaloid should not be readministered.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31356, 23315, 'Vinorelbine', 'Liver Diseases', 'Vinorelbine is extensively metabolized by the liver.  The pharmacokinetic disposition of vinorelbine in patients with hepatic impairment has not been assessed.  Therapy with vinorelbine should be administered cautiously and the dosage reduced in patients with compromised hepatic function.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31357, 23316, 'Vinorelbine', 'Liver Diseases', 'Vinorelbine is extensively metabolized by the liver.  The pharmacokinetic disposition of vinorelbine in patients with hepatic impairment has not been assessed.  Therapy with vinorelbine should be administered cautiously and the dosage reduced in patients with compromised hepatic function.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31358, 23317, 'Vinorelbine', 'Liver Diseases', 'Vinorelbine is extensively metabolized by the liver.  The pharmacokinetic disposition of vinorelbine in patients with hepatic impairment has not been assessed.  Therapy with vinorelbine should be administered cautiously and the dosage reduced in patients with compromised hepatic function.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31359, 23318, 'Vinorelbine', 'Liver Diseases', 'Vinorelbine is extensively metabolized by the liver.  The pharmacokinetic disposition of vinorelbine in patients with hepatic impairment has not been assessed.  Therapy with vinorelbine should be administered cautiously and the dosage reduced in patients with compromised hepatic function.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31360, 29366, 'Vinorelbine', 'Liver Diseases', 'Vinorelbine is extensively metabolized by the liver.  The pharmacokinetic disposition of vinorelbine in patients with hepatic impairment has not been assessed.  Therapy with vinorelbine should be administered cautiously and the dosage reduced in patients with compromised hepatic function.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31361, 29367, 'Vinorelbine', 'Liver Diseases', 'Vinorelbine is extensively metabolized by the liver.  The pharmacokinetic disposition of vinorelbine in patients with hepatic impairment has not been assessed.  Therapy with vinorelbine should be administered cautiously and the dosage reduced in patients with compromised hepatic function.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31362, 29368, 'Vinorelbine', 'Liver Diseases', 'Vinorelbine is extensively metabolized by the liver.  The pharmacokinetic disposition of vinorelbine in patients with hepatic impairment has not been assessed.  Therapy with vinorelbine should be administered cautiously and the dosage reduced in patients with compromised hepatic function.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31363, 29369, 'Vinorelbine', 'Liver Diseases', 'Vinorelbine is extensively metabolized by the liver.  The pharmacokinetic disposition of vinorelbine in patients with hepatic impairment has not been assessed.  Therapy with vinorelbine should be administered cautiously and the dosage reduced in patients with compromised hepatic function.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31364, 23315, 'Vinorelbine', 'Infections', 'Vinorelbine induces myelosuppression manifested by neutropenia, anemia and thrombocytopenia.  The use of vinorelbine may be contraindicated in patients with known infectious diseases.  Patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection.  Close clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31365, 23316, 'Vinorelbine', 'Infections', 'Vinorelbine induces myelosuppression manifested by neutropenia, anemia and thrombocytopenia.  The use of vinorelbine may be contraindicated in patients with known infectious diseases.  Patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection.  Close clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31366, 23317, 'Vinorelbine', 'Infections', 'Vinorelbine induces myelosuppression manifested by neutropenia, anemia and thrombocytopenia.  The use of vinorelbine may be contraindicated in patients with known infectious diseases.  Patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection.  Close clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31367, 23318, 'Vinorelbine', 'Infections', 'Vinorelbine induces myelosuppression manifested by neutropenia, anemia and thrombocytopenia.  The use of vinorelbine may be contraindicated in patients with known infectious diseases.  Patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection.  Close clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31368, 29366, 'Vinorelbine', 'Infections', 'Vinorelbine induces myelosuppression manifested by neutropenia, anemia and thrombocytopenia.  The use of vinorelbine may be contraindicated in patients with known infectious diseases.  Patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection.  Close clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31369, 29367, 'Vinorelbine', 'Infections', 'Vinorelbine induces myelosuppression manifested by neutropenia, anemia and thrombocytopenia.  The use of vinorelbine may be contraindicated in patients with known infectious diseases.  Patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection.  Close clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31370, 29368, 'Vinorelbine', 'Infections', 'Vinorelbine induces myelosuppression manifested by neutropenia, anemia and thrombocytopenia.  The use of vinorelbine may be contraindicated in patients with known infectious diseases.  Patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection.  Close clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31371, 29369, 'Vinorelbine', 'Infections', 'Vinorelbine induces myelosuppression manifested by neutropenia, anemia and thrombocytopenia.  The use of vinorelbine may be contraindicated in patients with known infectious diseases.  Patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection.  Close clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31372, 23315, 'Vinorelbine', 'Bone Marrow Failure Disorders', 'The use of vinorelbine is contraindicated in patients with neutrophil counts < 1000/mm3.  Vinorelbine induces dose-dependent myelosuppression, primarily neutropenia.  Therapy with vinorelbine should be administered with extreme caution and dosage modification considered in patients whose bone marrow reserve may be depressed by prior chemotherapy or irradiation or whose marrow function is recovering from previous cytotoxic therapy.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.   Close clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31373, 23316, 'Vinorelbine', 'Bone Marrow Failure Disorders', 'The use of vinorelbine is contraindicated in patients with neutrophil counts < 1000/mm3.  Vinorelbine induces dose-dependent myelosuppression, primarily neutropenia.  Therapy with vinorelbine should be administered with extreme caution and dosage modification considered in patients whose bone marrow reserve may be depressed by prior chemotherapy or irradiation or whose marrow function is recovering from previous cytotoxic therapy.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.   Close clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31374, 23317, 'Vinorelbine', 'Bone Marrow Failure Disorders', 'The use of vinorelbine is contraindicated in patients with neutrophil counts < 1000/mm3.  Vinorelbine induces dose-dependent myelosuppression, primarily neutropenia.  Therapy with vinorelbine should be administered with extreme caution and dosage modification considered in patients whose bone marrow reserve may be depressed by prior chemotherapy or irradiation or whose marrow function is recovering from previous cytotoxic therapy.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.   Close clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31375, 23318, 'Vinorelbine', 'Bone Marrow Failure Disorders', 'The use of vinorelbine is contraindicated in patients with neutrophil counts < 1000/mm3.  Vinorelbine induces dose-dependent myelosuppression, primarily neutropenia.  Therapy with vinorelbine should be administered with extreme caution and dosage modification considered in patients whose bone marrow reserve may be depressed by prior chemotherapy or irradiation or whose marrow function is recovering from previous cytotoxic therapy.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.   Close clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31376, 29366, 'Vinorelbine', 'Bone Marrow Failure Disorders', 'The use of vinorelbine is contraindicated in patients with neutrophil counts < 1000/mm3.  Vinorelbine induces dose-dependent myelosuppression, primarily neutropenia.  Therapy with vinorelbine should be administered with extreme caution and dosage modification considered in patients whose bone marrow reserve may be depressed by prior chemotherapy or irradiation or whose marrow function is recovering from previous cytotoxic therapy.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.   Close clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31377, 29367, 'Vinorelbine', 'Bone Marrow Failure Disorders', 'The use of vinorelbine is contraindicated in patients with neutrophil counts < 1000/mm3.  Vinorelbine induces dose-dependent myelosuppression, primarily neutropenia.  Therapy with vinorelbine should be administered with extreme caution and dosage modification considered in patients whose bone marrow reserve may be depressed by prior chemotherapy or irradiation or whose marrow function is recovering from previous cytotoxic therapy.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.   Close clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31378, 29368, 'Vinorelbine', 'Bone Marrow Failure Disorders', 'The use of vinorelbine is contraindicated in patients with neutrophil counts < 1000/mm3.  Vinorelbine induces dose-dependent myelosuppression, primarily neutropenia.  Therapy with vinorelbine should be administered with extreme caution and dosage modification considered in patients whose bone marrow reserve may be depressed by prior chemotherapy or irradiation or whose marrow function is recovering from previous cytotoxic therapy.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.   Close clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31379, 29369, 'Vinorelbine', 'Bone Marrow Failure Disorders', 'The use of vinorelbine is contraindicated in patients with neutrophil counts < 1000/mm3.  Vinorelbine induces dose-dependent myelosuppression, primarily neutropenia.  Therapy with vinorelbine should be administered with extreme caution and dosage modification considered in patients whose bone marrow reserve may be depressed by prior chemotherapy or irradiation or whose marrow function is recovering from previous cytotoxic therapy.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.   Close clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31380, 23315, 'Vinorelbine', 'Gastrointestinal Diseases', 'Severe and fatal paralytic ileus, constipation, intestinal obstruction, necrosis, and perforation occur in patients receiving vinorelbine injection.  Institute a prophylactic bowel regimen to mitigate potential constipation, bowel obstruction and/or paralytic ileus, considering adequate dietary fiber intake, hydration and routine use of stool softeners.  Caution and monitoring is advised in patients with history of gastrointestinal issues.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31381, 23316, 'Vinorelbine', 'Gastrointestinal Diseases', 'Severe and fatal paralytic ileus, constipation, intestinal obstruction, necrosis, and perforation occur in patients receiving vinorelbine injection.  Institute a prophylactic bowel regimen to mitigate potential constipation, bowel obstruction and/or paralytic ileus, considering adequate dietary fiber intake, hydration and routine use of stool softeners.  Caution and monitoring is advised in patients with history of gastrointestinal issues.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31382, 23317, 'Vinorelbine', 'Gastrointestinal Diseases', 'Severe and fatal paralytic ileus, constipation, intestinal obstruction, necrosis, and perforation occur in patients receiving vinorelbine injection.  Institute a prophylactic bowel regimen to mitigate potential constipation, bowel obstruction and/or paralytic ileus, considering adequate dietary fiber intake, hydration and routine use of stool softeners.  Caution and monitoring is advised in patients with history of gastrointestinal issues.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31383, 23318, 'Vinorelbine', 'Gastrointestinal Diseases', 'Severe and fatal paralytic ileus, constipation, intestinal obstruction, necrosis, and perforation occur in patients receiving vinorelbine injection.  Institute a prophylactic bowel regimen to mitigate potential constipation, bowel obstruction and/or paralytic ileus, considering adequate dietary fiber intake, hydration and routine use of stool softeners.  Caution and monitoring is advised in patients with history of gastrointestinal issues.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31384, 29366, 'Vinorelbine', 'Gastrointestinal Diseases', 'Severe and fatal paralytic ileus, constipation, intestinal obstruction, necrosis, and perforation occur in patients receiving vinorelbine injection.  Institute a prophylactic bowel regimen to mitigate potential constipation, bowel obstruction and/or paralytic ileus, considering adequate dietary fiber intake, hydration and routine use of stool softeners.  Caution and monitoring is advised in patients with history of gastrointestinal issues.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31385, 29367, 'Vinorelbine', 'Gastrointestinal Diseases', 'Severe and fatal paralytic ileus, constipation, intestinal obstruction, necrosis, and perforation occur in patients receiving vinorelbine injection.  Institute a prophylactic bowel regimen to mitigate potential constipation, bowel obstruction and/or paralytic ileus, considering adequate dietary fiber intake, hydration and routine use of stool softeners.  Caution and monitoring is advised in patients with history of gastrointestinal issues.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31386, 29368, 'Vinorelbine', 'Gastrointestinal Diseases', 'Severe and fatal paralytic ileus, constipation, intestinal obstruction, necrosis, and perforation occur in patients receiving vinorelbine injection.  Institute a prophylactic bowel regimen to mitigate potential constipation, bowel obstruction and/or paralytic ileus, considering adequate dietary fiber intake, hydration and routine use of stool softeners.  Caution and monitoring is advised in patients with history of gastrointestinal issues.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31387, 29369, 'Vinorelbine', 'Gastrointestinal Diseases', 'Severe and fatal paralytic ileus, constipation, intestinal obstruction, necrosis, and perforation occur in patients receiving vinorelbine injection.  Institute a prophylactic bowel regimen to mitigate potential constipation, bowel obstruction and/or paralytic ileus, considering adequate dietary fiber intake, hydration and routine use of stool softeners.  Caution and monitoring is advised in patients with history of gastrointestinal issues.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31388, 23315, 'Vinorelbine', 'Neuromuscular Diseases', 'Sensory and motor neuropathies, including severe neuropathies, occur in patients receiving vinorelbine.  Monitor patients for new or worsening signs and symptoms of neuropathy, such as paresthesia, hyperesthesia, hyporeflexia and muscle weakness while receiving vinorelbine.  Discontinue vinorelbine for CTCAE Grade 2 or greater neuropathy.  Therapy with vinorelbine should be administered cautiously in patients with or predisposed to neuropathy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31389, 23316, 'Vinorelbine', 'Neuromuscular Diseases', 'Sensory and motor neuropathies, including severe neuropathies, occur in patients receiving vinorelbine.  Monitor patients for new or worsening signs and symptoms of neuropathy, such as paresthesia, hyperesthesia, hyporeflexia and muscle weakness while receiving vinorelbine.  Discontinue vinorelbine for CTCAE Grade 2 or greater neuropathy.  Therapy with vinorelbine should be administered cautiously in patients with or predisposed to neuropathy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31390, 23317, 'Vinorelbine', 'Neuromuscular Diseases', 'Sensory and motor neuropathies, including severe neuropathies, occur in patients receiving vinorelbine.  Monitor patients for new or worsening signs and symptoms of neuropathy, such as paresthesia, hyperesthesia, hyporeflexia and muscle weakness while receiving vinorelbine.  Discontinue vinorelbine for CTCAE Grade 2 or greater neuropathy.  Therapy with vinorelbine should be administered cautiously in patients with or predisposed to neuropathy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31391, 23318, 'Vinorelbine', 'Neuromuscular Diseases', 'Sensory and motor neuropathies, including severe neuropathies, occur in patients receiving vinorelbine.  Monitor patients for new or worsening signs and symptoms of neuropathy, such as paresthesia, hyperesthesia, hyporeflexia and muscle weakness while receiving vinorelbine.  Discontinue vinorelbine for CTCAE Grade 2 or greater neuropathy.  Therapy with vinorelbine should be administered cautiously in patients with or predisposed to neuropathy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31392, 29366, 'Vinorelbine', 'Neuromuscular Diseases', 'Sensory and motor neuropathies, including severe neuropathies, occur in patients receiving vinorelbine.  Monitor patients for new or worsening signs and symptoms of neuropathy, such as paresthesia, hyperesthesia, hyporeflexia and muscle weakness while receiving vinorelbine.  Discontinue vinorelbine for CTCAE Grade 2 or greater neuropathy.  Therapy with vinorelbine should be administered cautiously in patients with or predisposed to neuropathy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31393, 29367, 'Vinorelbine', 'Neuromuscular Diseases', 'Sensory and motor neuropathies, including severe neuropathies, occur in patients receiving vinorelbine.  Monitor patients for new or worsening signs and symptoms of neuropathy, such as paresthesia, hyperesthesia, hyporeflexia and muscle weakness while receiving vinorelbine.  Discontinue vinorelbine for CTCAE Grade 2 or greater neuropathy.  Therapy with vinorelbine should be administered cautiously in patients with or predisposed to neuropathy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31394, 29368, 'Vinorelbine', 'Neuromuscular Diseases', 'Sensory and motor neuropathies, including severe neuropathies, occur in patients receiving vinorelbine.  Monitor patients for new or worsening signs and symptoms of neuropathy, such as paresthesia, hyperesthesia, hyporeflexia and muscle weakness while receiving vinorelbine.  Discontinue vinorelbine for CTCAE Grade 2 or greater neuropathy.  Therapy with vinorelbine should be administered cautiously in patients with or predisposed to neuropathy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31395, 29369, 'Vinorelbine', 'Neuromuscular Diseases', 'Sensory and motor neuropathies, including severe neuropathies, occur in patients receiving vinorelbine.  Monitor patients for new or worsening signs and symptoms of neuropathy, such as paresthesia, hyperesthesia, hyporeflexia and muscle weakness while receiving vinorelbine.  Discontinue vinorelbine for CTCAE Grade 2 or greater neuropathy.  Therapy with vinorelbine should be administered cautiously in patients with or predisposed to neuropathy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31396, 1421, 'Beta carotene', 'Liver Diseases', 'Vitamin A (including beta-carotene) is fat soluble and requires bile for adequate intestinal absorption.  Hepatic and/or biliary dysfunction decrease the absorption of vitamin A.  Vitamin A is metabolized by the liver and primarily excreted in bile and feces. Beta-carotene is primarily metabolized in the GI mucosa to vitamin A. Hepatic and/or biliary impairment can alter the metabolic and therapeutic activity of Vitamin A.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31397, 1421, 'Beta carotene', 'Malabsorption Syndromes', 'Absorption of vitamin A  depends on the presence of bile and absorbable fat in the GI tract.  Prolonged fat malabsorption (cystic fibrosis, hepatic cirrhosis, sprue) or malabsorption syndromes (celiac disease, GI resection) can decrease the absorption of Vitamin A.  Water- miscible vitamin A formulations may be an appropriate alternative in malabsorption conditions for certain conditions requiring vitamin A therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31398, 0, 'Vismodegib', 'Musculoskeletal Diseases', 'Musculoskeletal adverse reactions, which may be accompanied by serum creatine kinase elevations have been reported with the use of drugs that inhibit the hedgehog pathway.  It is recommended to obtain serum creatine kinase levels and renal function tests prior to initiating therapy, periodically during treatment, and as clinically indicated.  Care should be taken when prescribing these agents to patients presenting musculoskeletal pain or myalgia.  Temporary dose interruption or discontinuation of therapy may be required based on the severity of musculoskeletal adverse reactions.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31399, 1172, 'Vitamin A', 'Liver Diseases', 'Vitamin A (including beta-carotene) is fat soluble and requires bile for adequate intestinal absorption.  Hepatic and/or biliary dysfunction decrease the absorption of vitamin A.  Vitamin A is metabolized by the liver and primarily excreted in bile and feces. Beta-carotene is primarily metabolized in the GI mucosa to vitamin A. Hepatic and/or biliary impairment can alter the metabolic and therapeutic activity of Vitamin A.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31400, 29488, 'Vitamin A', 'Liver Diseases', 'Vitamin A (including beta-carotene) is fat soluble and requires bile for adequate intestinal absorption.  Hepatic and/or biliary dysfunction decrease the absorption of vitamin A.  Vitamin A is metabolized by the liver and primarily excreted in bile and feces. Beta-carotene is primarily metabolized in the GI mucosa to vitamin A. Hepatic and/or biliary impairment can alter the metabolic and therapeutic activity of Vitamin A.', '3', '', 'DDInter', 0);
